{"pmid":32407189,"title":"Recommendation of fecal specimen for routine molecular detection of SARS-CoV-2 and for COVID-19 discharge criteria.","text":["Recommendation of fecal specimen for routine molecular detection of SARS-CoV-2 and for COVID-19 discharge criteria.","Pathog Glob Health","Ahamed Mim, Moonmoon","Naznin Rakhi, Nadira","Saha, Otun","Rahaman, Md Mizanur","32407189"],"journal":"Pathog Glob Health","authors":["Ahamed Mim, Moonmoon","Naznin Rakhi, Nadira","Saha, Otun","Rahaman, Md Mizanur"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32407189","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1080/20477724.2020.1765651","topics":["Diagnosis"],"weight":1,"_version_":1666802845340401664,"score":9.490897,"similar":[{"pmid":32379723,"title":"Molecular detection of SARS-CoV-2 in formalin fixed paraffin embedded specimens.","text":["Molecular detection of SARS-CoV-2 in formalin fixed paraffin embedded specimens.","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of human coronavirus disease 2019 (COVID-19), emerged in Wuhan, China in December 2019. The virus rapidly spread globally, resulting in a public-health crisis including more than 3.1 million cases and 224,000 deaths as of May 1, 2020. Here, we describe the identification and evaluation of commercially available reagents and assays for the molecular detection of SARS-CoV-2 in infected formalin fixed paraffin embedded (FFPE) cell pellets. We identified a suitable rabbit polyclonal anti-SARS-CoV spike protein antibody and a mouse monoclonal anti-SARS-CoV nucleocapsid protein (NP) antibody for cross detection of the respective SARS-CoV-2 proteins by immunohistochemistry (IHC) and immunofluorescence assay (IFA). Next, we established RNAscope in situ hybridization (ISH) to detect SARS-CoV-2 RNA. Furthermore, we established a multiplex fluorescence ISH (mFISH) to detect positive-sense SARS-CoV-2 RNA and negative-sense SARS-CoV-2 RNA (a replicative intermediate indicating viral replication). Finally, we developed a dual staining assay using IHC and ISH to detect SARS-CoV-2 antigen and RNA in the same FFPE section. These reagents and assays will accelerate COVID-19 pathogenesis studies in humans and in COVID-19 animal models.","JCI Insight","Liu, Jun","Babka, April M","Kearney, Brian J","Radoshitzky, Sheli R","Kuhn, Jens H","Zeng, Xiankun","32379723"],"abstract":["Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of human coronavirus disease 2019 (COVID-19), emerged in Wuhan, China in December 2019. The virus rapidly spread globally, resulting in a public-health crisis including more than 3.1 million cases and 224,000 deaths as of May 1, 2020. Here, we describe the identification and evaluation of commercially available reagents and assays for the molecular detection of SARS-CoV-2 in infected formalin fixed paraffin embedded (FFPE) cell pellets. We identified a suitable rabbit polyclonal anti-SARS-CoV spike protein antibody and a mouse monoclonal anti-SARS-CoV nucleocapsid protein (NP) antibody for cross detection of the respective SARS-CoV-2 proteins by immunohistochemistry (IHC) and immunofluorescence assay (IFA). Next, we established RNAscope in situ hybridization (ISH) to detect SARS-CoV-2 RNA. Furthermore, we established a multiplex fluorescence ISH (mFISH) to detect positive-sense SARS-CoV-2 RNA and negative-sense SARS-CoV-2 RNA (a replicative intermediate indicating viral replication). Finally, we developed a dual staining assay using IHC and ISH to detect SARS-CoV-2 antigen and RNA in the same FFPE section. These reagents and assays will accelerate COVID-19 pathogenesis studies in humans and in COVID-19 animal models."],"journal":"JCI Insight","authors":["Liu, Jun","Babka, April M","Kearney, Brian J","Radoshitzky, Sheli R","Kuhn, Jens H","Zeng, Xiankun"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32379723","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1172/jci.insight.139042","keywords":["covid-19","molecular diagnosis","molecular pathology","virology"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Paraffin","Formaldehyde"],"topics":["Diagnosis"],"weight":1,"_version_":1666597097288237056,"score":44.1897},{"pmid":32341143,"title":"Comparison of Four Molecular In Vitro Diagnostic Assays for the Detection of SARS-CoV-2 in Nasopharyngeal Specimens.","text":["Comparison of Four Molecular In Vitro Diagnostic Assays for the Detection of SARS-CoV-2 in Nasopharyngeal Specimens.","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the novel human coronavirus that causes coronavirus disease 2019 (COVID-19), was first discovered in December 2019 as the cause of an outbreak of pneumonia in the city of Wuhan, Hubei province, China. The clinical presentation of COVID-19 is fairly non-specific, and symptoms overlap with other seasonal respiratory infections concurrently circulating in the population. Furthermore, it is estimated that up to 80% of infected individuals experience mild symptoms or are asymptomatic, confounding efforts to reliably diagnose COVID-19 empirically. To support infection control measures, there is an urgent need for rapid and accurate molecular diagnostics to identify COVID-19 positive patients. In the present study, we have evaluated the analytical sensitivity and clinical performance of four SARS-CoV-2 molecular diagnostic assays granted Emergency Use Authorization by the FDA using nasopharyngeal swabs from symptomatic patients: the New York SARS-CoV-2 Real-time Reverse Transcriptase (RT)-PCR Diagnostic Panel (Modified CDC), the Simplexa COVID-19 Direct (Diasorin Molecular), GenMark ePlex SARS-CoV-2 assay (GenMark) and the Hologic Panther Fusion(R) SARS-CoV-2 assay (Hologic). This information is crucial for both laboratories and clinical teams, as decisions on which testing platform to implement are made.","J Clin Microbiol","Zhen, Wei","Manji, Ryhana","Smith, Elizabeth","Berry, Gregory J","32341143"],"abstract":["Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the novel human coronavirus that causes coronavirus disease 2019 (COVID-19), was first discovered in December 2019 as the cause of an outbreak of pneumonia in the city of Wuhan, Hubei province, China. The clinical presentation of COVID-19 is fairly non-specific, and symptoms overlap with other seasonal respiratory infections concurrently circulating in the population. Furthermore, it is estimated that up to 80% of infected individuals experience mild symptoms or are asymptomatic, confounding efforts to reliably diagnose COVID-19 empirically. To support infection control measures, there is an urgent need for rapid and accurate molecular diagnostics to identify COVID-19 positive patients. In the present study, we have evaluated the analytical sensitivity and clinical performance of four SARS-CoV-2 molecular diagnostic assays granted Emergency Use Authorization by the FDA using nasopharyngeal swabs from symptomatic patients: the New York SARS-CoV-2 Real-time Reverse Transcriptase (RT)-PCR Diagnostic Panel (Modified CDC), the Simplexa COVID-19 Direct (Diasorin Molecular), GenMark ePlex SARS-CoV-2 assay (GenMark) and the Hologic Panther Fusion(R) SARS-CoV-2 assay (Hologic). This information is crucial for both laboratories and clinical teams, as decisions on which testing platform to implement are made."],"journal":"J Clin Microbiol","authors":["Zhen, Wei","Manji, Ryhana","Smith, Elizabeth","Berry, Gregory J"],"date":"2020-04-29T11:00:00Z","year":2020,"_id":"32341143","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1128/JCM.00743-20","locations":["Wuhan","Hubei","China","New York"],"countries":["United States","China"],"countries_codes":["USA|United States","CHN|China"],"topics":["Diagnosis"],"weight":1,"_version_":1666138495765184515,"score":41.01804},{"pmid":32124995,"title":"Fecal specimen diagnosis 2019 novel coronavirus-infected pneumonia.","text":["Fecal specimen diagnosis 2019 novel coronavirus-infected pneumonia.","The emergence and spread of 2019 novel coronavirus-infected pneumonia (COVID-19) from Wuhan, China, it has spread globally. We extracted the data on 14 patients with laboratory-confirmed COVID-19 from Jinhua Municipal Central hospital through 27 January 2020. We found that compared to pharyngeal swab specimens, nucleic acid detection of COVID-19 in fecal specimens was equally accurate. And we found that patients with a positive stool test did not experience gastrointestinal symptoms and had nothing to do with the severity of the lung infection. These results may help to understand the clinical diagnosis and the changes in clinical parameters of COVID-19.","J Med Virol","Zhang, JingCheng","Wang, SaiBin","Xue, YaDong","32124995"],"abstract":["The emergence and spread of 2019 novel coronavirus-infected pneumonia (COVID-19) from Wuhan, China, it has spread globally. We extracted the data on 14 patients with laboratory-confirmed COVID-19 from Jinhua Municipal Central hospital through 27 January 2020. We found that compared to pharyngeal swab specimens, nucleic acid detection of COVID-19 in fecal specimens was equally accurate. And we found that patients with a positive stool test did not experience gastrointestinal symptoms and had nothing to do with the severity of the lung infection. These results may help to understand the clinical diagnosis and the changes in clinical parameters of COVID-19."],"journal":"J Med Virol","authors":["Zhang, JingCheng","Wang, SaiBin","Xue, YaDong"],"date":"2020-03-04T11:00:00Z","year":2020,"_id":"32124995","source":"PubMed","week":"202010|Mar 02 - Mar 08","doi":"10.1002/jmv.25742","keywords":["coronavirus","dissemination","nervous system","pathogenesis","virus classification"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis"],"weight":1,"_version_":1666138492811345921,"score":40.474274}]}